**Core Concept**
The underlying principle being tested is the understanding of **selective serotonin reuptake inhibitors (SSRIs)** and their withdrawal symptoms, also known as **antidepressant discontinuation syndrome**. This occurs when these medications are stopped abruptly after prolonged use.

**Why the Correct Answer is Right**
The correct answer, **fluoxetine**, has a longer half-life and an active metabolite, **norfluoxetine**, which extends its action. This pharmacokinetic property allows for a more gradual decline in serotonin reuptake inhibition when the medication is stopped, thereby reducing the risk of **discontinuation symptoms**.

**Why Each Wrong Option is Incorrect**
**Option A:** Other SSRIs have shorter half-lives, making them more prone to causing withdrawal symptoms upon cessation.
**Option B:** Similar to Option A, certain SSRIs are known for their shorter half-lives and higher risk of discontinuation symptoms.
**Option D:** This option would also have a higher risk due to its pharmacokinetic profile being less favorable than fluoxetine in terms of minimizing withdrawal symptoms.

**Clinical Pearl / High-Yield Fact**
It's crucial to remember that **fluoxetine**, due to its long half-life and active metabolite, is often chosen when there's a concern about discontinuation symptoms, making it a valuable piece of information for managing patients on SSRIs.

**Correct Answer:** D. fluoxetine.